Martin Storr, MD - Publications

Affiliations: 
Medicine University of Calgary, Calgary, Alberta, Canada 

159 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Szymaszkiewicz A, Włodarczyk J, Wasilewski A, Di Marzo V, Storr M, Fichna J, Zielińska M. Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 32002574 DOI: 10.1007/s00210-020-01829-x  0.52
2020 Kienzl M, Storr M, Schicho R. Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. Clinical and Translational Gastroenterology. PMID 31899693 DOI: 10.14309/ctg.0000000000000120  0.36
2019 Fabisiak A, Włodarczyk M, Fabisiak N, Storr M, Fichna J. Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis. Journal of Gastrointestinal and Liver Diseases : Jgld. 28: 473-481. PMID 31826058 DOI: 10.15403/jgld-265  0.52
2019 Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J. Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43]. European Journal of Pharmacology. 172656. PMID 31519354 DOI: 10.1016/j.ejphar.2019.172656  0.52
2019 Andrews CN, Devlin SM, Le Foll B, Fischer B, Tse F, Storr M, Congly SE. Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders. Journal of the Canadian Association of Gastroenterology. 2: 37-43. PMID 31294362 DOI: 10.1093/jcag/gwy064  0.6
2018 Szymaszkiewicz A, Storr M, Fichna J, Zielinska M. Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. e13526. PMID 30549162 DOI: 10.1111/nmo.13526  0.52
2018 Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J. The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. European Journal of Pharmacology. PMID 30121173 DOI: 10.1016/j.ejphar.2018.08.016  0.52
2018 Szymaszkiewicz A, Zielinska M, Li K, Ramanathan M, Alam S, Hou DR, Fichna J, Storr M. Novel derivatives of 1,2,3-triazole, cannabinoid-1 receptor ligands modulate gastrointestinal motility in mice. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 29404698 DOI: 10.1007/s00210-018-1465-9  0.52
2017 Binienda A, Storr M, Fichna J, Salaga M. Efficacy and safety of serotonin receptor ligands in the treatment of irritable bowel syndrome: a review. Current Drug Targets. PMID 29284389 DOI: 10.2174/1389450119666171227225408  0.52
2017 Fabisiak A, Włodarczyk J, Fabisiak N, Storr M, Fichna J. Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal. Journal of Neurogastroenterology and Motility. PMID 28551943 DOI: 10.5056/jnm16203  0.52
2017 Wasilewski A, Lewandowska U, Mosinska P, Watala C, Storr M, Fichna J, Venkatesan T. Cannabinoid Receptor Type 1 and mu-Opioid Receptor Polymorphisms Are Associated With Cyclic Vomiting Syndrome. The American Journal of Gastroenterology. PMID 28349993 DOI: 10.1038/ajg.2017.73  0.52
2017 Hasenoehrl C, Storr M, Schicho R. Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Expert Review of Gastroenterology & Hepatology. 11: 329-337. PMID 28276820 DOI: 10.1080/17474124.2017.1292851  0.36
2017 Mosińska P, Zatorski H, Storr M, Fichna J. Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor Agonists. Journal of Neurogastroenterology and Motility. PMID 28238253 DOI: 10.5056/jnm16183  0.52
2017 Taschler U, Hasenoehrl C, Storr M, Schicho R. Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance. Handbook of Experimental Pharmacology. PMID 28161834 DOI: 10.1007/164_2016_105  0.36
2016 Jarmuż A, Banaszek M, Leń K, Storr M, Zielińska M, Fichna J. Dietary Fats and Oils in India. Current Diabetes Reviews. PMID 27501784  0.52
2016 Jarmuż A, Banaszek M, Leń K, Storr M, Zielińska M, Fichna J. The role of MOP and DOP receptors in treatment of diarrhea-predominant irritable bowel syndrome. Mini Reviews in Medicinal Chemistry. PMID 27494245  0.52
2016 Jarmuż A, Banaszek M, Leń K, Storr M, Zielińska M, Fichna J. The role of MOP and DOP receptors in treatment of diarrhea-predominant irritable bowel syndrome. Mini Reviews in Medicinal Chemistry. PMID 27494159  0.52
2016 Krohn RM, Parsons SA, Fichna J, Patel KD, Yates RM, Sharkey KA, Storr MA. Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment. Journal of Inflammation (London, England). 13: 21. PMID 27418880 DOI: 10.1186/s12950-016-0129-0  1
2016 Sobolewska-Włodarczyk A, Włodarczyk M, Storr M, Fichna J. Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Therapeutics and Clinical Risk Management. 12: 771-5. PMID 27257381 DOI: 10.2147/TCRM.S83722  0.52
2016 Mosińska P, Socała K, Nieoczym D, Laudon M, Storr M, Fichna J, Wlaź P. Anticonvulsant activity of melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, in mice. Behavioural Brain Research. PMID 27016427 DOI: 10.1016/j.bbr.2016.03.036  0.52
2016 Zielińska M, Jarmuż A, Sałaga M, Kordek R, Laudon M, Storr M, Fichna J. Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 26899972 DOI: 10.1007/s00210-016-1214-x  0.52
2016 Salaga M, Storr M, Martemyanov KA, Fichna J. RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. PMID 26817719 DOI: 10.1002/bies.201500118  0.52
2015 Abalo R, Chen C, Vera G, Fichna J, Thakur GA, López-Pérez AE, Makriyannis A, Martín-Fontelles MI, Storr M. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. PMID 26387676 DOI: 10.1111/nmo.12668  1
2015 Mazurak N, Broelz E, Storr M, Enck P. Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It? Journal of Neurogastroenterology and Motility. 21: 471-85. PMID 26351253 DOI: 10.5056/jnm15071  1
2015 Fichna J, Poole DP, Veldhuis N, MacEachern SJ, Saur D, Zakrzewski PK, Cygankiewicz AI, Mokrowiecka A, Małecka-Panas E, Krajewska WM, Liedtke W, Steinhoff MS, Timmermans JP, Bunnett NW, Sharkey KA, ... Storr MA, et al. Transient receptor potential vanilloid 4 inhibits mouse colonic motility by activating NO-dependent enteric neurotransmission. Journal of Molecular Medicine (Berlin, Germany). PMID 26330151 DOI: 10.1007/s00109-015-1336-5  1
2015 Mosińska P, Storr M, Fichna J. The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective. Therapeutic Advances in Gastroenterology. 8: 278-84. PMID 26327918 DOI: 10.1177/1756283X15587866  1
2015 Zoller V, Laguna AL, Prazeres Da Costa O, Buch T, Göke B, Storr M. [Fecal microbiota transfer (FMT) in a patient with refractory irritable bowel syndrome]. Deutsche Medizinische Wochenschrift (1946). 140: 1232-6. PMID 26261935 DOI: 10.1055/s-0041-103798  1
2015 Sibaev A, Fichna J, Saur D, Yuece B, Timmermans JP, Storr M. Nociceptin effect on intestinal motility depends on opioid-receptor like-1 receptors and nitric oxide synthase co-localization. World Journal of Gastrointestinal Pharmacology and Therapeutics. 6: 73-83. PMID 26261735 DOI: 10.4292/wjgpt.v6.i3.73  0.52
2015 Stančić A, Jandl K, Hasenöhrl C, Reichmann F, Marsche G, Schuligoi R, Heinemann A, Storr M, Schicho R. The GPR55 antagonist CID16020046 protects against intestinal inflammation. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 27: 1432-45. PMID 26227635 DOI: 10.1111/nmo.12639  1
2015 Mosińska P, Fichna J, Storr M. Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation. World Journal of Gastroenterology. 21: 7436-42. PMID 26139989 DOI: 10.3748/wjg.v21.i24.7436  1
2015 Bokic T, Storr M, Schicho R. Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview. Pharmacology. 96: 76-85. PMID 26139425 DOI: 10.1159/000435816  1
2015 Taschler U, Eichmann TO, Radner FP, Grabner GF, Wolinski H, Storr M, Lass A, Schicho R, Zimmermann R. Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity. British Journal of Pharmacology. 172: 4419-29. PMID 26075589 DOI: 10.1111/bph.13224  1
2015 Jarmuż A, Zielińska M, Storr M, Fichna J. Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 27: 1057-68. PMID 25930667 DOI: 10.1111/nmo.12574  1
2015 Wasilewski A, Zieli?ska M, Storr M, Fichna J. Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 21: 1674-82. PMID 25822014 DOI: 10.1097/MIB.0000000000000364  1
2015 Bashashati M, Nasser Y, Keenan CM, Ho W, Piscitelli F, Nalli M, Mackie K, Storr MA, Di Marzo V, Sharkey KA. Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. British Journal of Pharmacology. 172: 3099-111. PMID 25684407 DOI: 10.1111/bph.13114  1
2015 Schicho R, Marsche G, Storr M. Cardiovascular complications in inflammatory bowel disease. Current Drug Targets. 16: 181-8. PMID 25642719  1
2015 Keenan CM, Storr MA, Thakur GA, Wood JT, Wager-Miller J, Straiker A, Eno MR, Nikas SP, Bashashati M, Hu H, Mackie K, Makriyannis A, Sharkey KA. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. British Journal of Pharmacology. 172: 2406-18. PMID 25572435 DOI: 10.1111/bph.13069  1
2015 Wasilewski A, Storr M, Zieli?ska M, Fichna J. Role of G protein-coupled orphan receptors in intestinal inflammation: novel targets in inflammatory bowel diseases. Inflammatory Bowel Diseases. 21: 666-73. PMID 25461621 DOI: 10.1097/MIB.0000000000000258  1
2015 Storr M. Teduglutide is the first drug for the specific treatment of short bowel syndrome | Teduglutid ist das erste Arzneimittel zur spezifischen Behandlung des Kurzdarmsyndroms Arzneimitteltherapie. 33: 154-155.  1
2015 Storr M. Regorafenib for metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumor (GIST) | Regorafenib beim metastasierten kolorektalen Karzinom (mCRC) und beim gastrointestinalen Stromatumor (GIST) Arzneimitteltherapie. 33: 15-17.  1
2014 Fichna J, Bawa M, Thakur GA, Tichkule R, Makriyannis A, McCafferty DM, Sharkey KA, Storr M. Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors. Plos One. 9: e109115. PMID 25275313 DOI: 10.1371/journal.pone.0109115  1
2014 Storr M. [Diet improves symptoms of diabetic gastroparesis]. Mmw Fortschritte Der Medizin. 156: 36. PMID 25195403 DOI: 10.1007/s15006-014-3336-8  1
2014 Chen C, Yu Z, Li Y, Fichna J, Storr M. Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications. The American Journal of Chinese Medicine. 42: 1053-70. PMID 25183302 DOI: 10.1142/S0192415X14500669  1
2014 Salaga M, Storr M, Fichna J. Cross-talk between serotonin and cannabinoid signaling in the gut, new insights and future perspectives. Pain. 155: 2204-5. PMID 25109671 DOI: 10.1016/j.pain.2014.08.002  1
2014 Fichna J, Sobczak M, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, Cenac N, Sa?aga M, Timmermans JP, Vergnolle N, Ma?ecka-Panas E, Krajewska WM, Storr M. Activation of the endogenous nociceptin system by selective nociceptin receptor agonist SCH 221510 produces antitransit and antinociceptive effect: a novel strategy for treatment of diarrhea-predominant IBS. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 26: 1539-50. PMID 25041572 DOI: 10.1111/nmo.12390  0.56
2014 Storr M. [How to proceed when the pathologist does not confirm suspected Barrett esophagus?]. Mmw Fortschritte Der Medizin. 156: 33. PMID 24930224  1
2014 Storr M. [Smoking cessation improves reflux symptoms]. Mmw Fortschritte Der Medizin. 156: 30. PMID 24912259 DOI: 10.1007/s15006-014-2761-z  1
2014 Sibaev A, Yuece B, Allescher HD, Saur D, Storr M, Kurjak M. The endocannabinoid anandamide regulates the peristaltic reflex by reducing neuro-neuronal and neuro-muscular neurotransmission in ascending myenteric reflex pathways in rats. Pharmacological Reports : Pr. 66: 256-63. PMID 24911079 DOI: 10.1016/j.pharep.2013.09.008  1
2014 Storr M. [Irritable bowel syndrome - diet modifies the symptoms]. Mmw Fortschritte Der Medizin. 156: 33. PMID 24908882  1
2014 SaÅ‚aga M, Polepally PR, Sobczak M, Grzywacz D, Kamysz W, Sibaev A, Storr M, Do Rego JC, Zjawiony JK, Fichna J. Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. The Journal of Pharmacology and Experimental Therapeutics. 350: 69-78. PMID 24891526 DOI: 10.1124/jpet.114.214239  1
2014 Venkatesan T, Sengupta J, Lodhi A, Schroeder A, Adams K, Hogan WJ, Wang Y, Andrews C, Storr M. An Internet survey of marijuana and hot shower use in adults with cyclic vomiting syndrome (CVS). Experimental Brain Research. 232: 2563-70. PMID 24792504 DOI: 10.1007/s00221-014-3967-0  1
2014 Bashashati M, Hejazi RA, Andrews CN, Storr MA. Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia? Canadian Journal of Gastroenterology & Hepatology. 28: 335-41. PMID 24719900  0.56
2014 Storr M. [In Process Citation]. Medizinische Monatsschrift FüR Pharmazeuten. 37: 78-9. PMID 24624612  1
2014 Chen C, Fichna J, Laudon M, Storr M. Antinociceptive effects of novel melatonin receptor agonists in mouse models of abdominal pain. World Journal of Gastroenterology : Wjg. 20: 1298-304. PMID 24574803 DOI: 10.3748/wjg.v20.i5.1298  0.56
2014 Sa?aga M, Mokrowiecka A, Zakrzewski PK, Cygankiewicz A, Leishman E, Sobczak M, Zatorski H, Ma?ecka-Panas E, Kordek R, Storr M, Krajewska WM, Bradshaw HB, Fichna J. Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). Journal of Crohn's & Colitis. 8: 998-1009. PMID 24530133 DOI: 10.1016/j.crohns.2014.01.025  1
2014 Fichna J, SaÅ‚aga M, Stuart J, Saur D, Sobczak M, Zatorski H, Timmermans JP, Bradshaw HB, Ahn K, Storr MA. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 26: 470-81. PMID 24460851 DOI: 10.1111/nmo.12272  0.56
2014 Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflammatory Bowel Diseases. 20: 472-80. PMID 24407485 DOI: 10.1097/01.MIB.0000440982.79036.d6  1
2014 Schicho R, Storr M. IBD: Patients with IBD find symptom relief in the Cannabis field. Nature Reviews. Gastroenterology & Hepatology. 11: 142-3. PMID 24366227 DOI: 10.1038/nrgastro.2013.245  1
2014 Schicho R, Storr M. Cannabis finds its way into treatment of Crohn's disease. Pharmacology. 93: 1-3. PMID 24356243 DOI: 10.1159/000356512  1
2014 Sobczak M, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, SaÅ‚aga M, Storr M, Kordek R, MaÅ‚ecka-Panas E, Krajewska WM, Fichna J. Anti-inflammatory and antinociceptive action of an orally available nociceptin receptor agonist SCH 221510 in a mouse model of inflammatory bowel diseases. The Journal of Pharmacology and Experimental Therapeutics. 348: 401-9. PMID 24345466 DOI: 10.1124/jpet.113.209825  1
2014 Alfadda AA, Shaffer EA, Urbanski SJ, Storr MA. Eosinophilic colitis is a sporadic self-limited disease of middle-aged people: a population-based study. Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland. 16: 123-9. PMID 24138295 DOI: 10.1111/codi.12464  1
2014 Füllhase C, Campeau L, Sibaev A, Storr M, Hennenberg M, Gratzke C, Stief C, Hedlund P, Andersson KE. Bladder function in a cannabinoid receptor type 1 knockout mouse. Bju International. 113: 144-51. PMID 24053792 DOI: 10.1111/bju.12350  1
2014 Sobczak M, SaÅ‚aga M, Storr MA, Fichna J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. Journal of Gastroenterology. 49: 24-45. PMID 23397116 DOI: 10.1007/s00535-013-0753-x  1
2014 Storr M. Tests on fecal occult blood fail in the physician's everyday practice: Commentary | Tests auf okkultes blut im stuhl versagen im praxisalltag: Kommentar Mmw-Fortschritte Der Medizin. 156: 28.  1
2014 Storr M. Vedolizumab in inflammatory bowel diseases | Vedolizumab bei chronischentziindlichen Darmerkrankungen Arzneimitteltherapie. 32: 618-627.  1
2014 Storr M. Chronic inflammatory bowel diseases: Is cannabis helpful in the treatment of Crohn's disease? | Cannabis hilfreich in der therapie des Morbus Crohn? Medizinische Monatsschrift Fur Pharmazeuten. 37: 144-145.  1
2014 Storr M. Men with diarrhea-predominant irritable bowel syndrome: Ramosetron improves stool consistency | Männer mit diarrhö-betontem reizdarmsyndrom: Ramosetron verbessert die stuhlkonsistenz Arzneimitteltherapie. 32: 138-139.  1
2013 Storr M. [Functional heartburn--update 2013]. Mmw Fortschritte Der Medizin. 155: 100-3. PMID 24934062  1
2013 Fichna J, Wood JT, Papanastasiou M, Vadivel SK, Oprocha P, SaÅ‚aga M, Sobczak M, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, MaÅ‚ecka-Panas E, Krajewska WM, KoÅ›cielniak P, Makriyannis A, Storr MA. Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. Plos One. 8: e85073. PMID 24386448 DOI: 10.1371/journal.pone.0085073  0.56
2013 Storr M. [Short bowel syndrome. GLP-2 analog teduglutide]. Medizinische Monatsschrift FüR Pharmazeuten. 36: 343-5. PMID 24069647  1
2013 Yan LM, Velkova A, Tatarek-Nossol M, Rammes G, Sibaev A, Andreetto E, Kracklauer M, Bakou M, Malideli E, Göke B, Schirra J, Storr M, Kapurniotu A. Selectively N-methylated soluble IAPP mimics as potent IAPP receptor agonists and nanomolar inhibitors of cytotoxic self-assembly of both IAPP and Aβ40. Angewandte Chemie (International Ed. in English). 52: 10378-83. PMID 23956012 DOI: 10.1002/anie.201302840  1
2013 Linton MS, Zhao L, Gui X, Storr M, Andrews CN. Lichen planus is an uncommon cause of nonspecific proximal esophageal inflammation. Gut and Liver. 7: 401-5. PMID 23898378 DOI: 10.5009/gnl.2013.7.4.401  1
2013 Li YY, Cao MH, Goetz B, Chen CQ, Feng YJ, Chen CJ, Kasparek MS, Sibaev A, Storr M, Kreis ME. The dual effect of cannabinoid receptor-1 deficiency on the murine postoperative ileus. Plos One. 8: e67427. PMID 23844009 DOI: 10.1371/journal.pone.0067427  1
2013 Sobczak M, SaÅ‚aga M, Storr M, Fichna J. Nociceptin / orphanin FQ (NOP) receptors as novel potential target in the treatment of gastrointestinal diseases. Current Drug Targets. 14: 1203-9. PMID 23773151 DOI: 10.2174/13894501113149990174  1
2013 Storr M. [Helicobacter pylori - Update 2013]. Medizinische Monatsschrift FüR Pharmazeuten. 36: 172-6; quiz 177-8. PMID 23758027  1
2013 Stewart MJ, Shaffer E, Urbanski SJ, Beck PL, Storr MA. The association between celiac disease and eosinophilic esophagitis in children and adults. Bmc Gastroenterology. 13: 96. PMID 23721294 DOI: 10.1186/1471-230X-13-96  1
2013 Fichna J, Sibaev A, SaÅ‚aga M, Sobczak M, Storr M. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 25: e550-9. PMID 23692073 DOI: 10.1111/nmo.12158  1
2013 Storr M, Vogel HJ, Schicho R. Metabolomics: is it useful for inflammatory bowel diseases? Current Opinion in Gastroenterology. 29: 378-83. PMID 23624676 DOI: 10.1097/MOG.0b013e328361f488  1
2013 Li K, Fichna J, Schicho R, Saur D, Bashashati M, Mackie K, Li Y, Zimmer A, Göke B, Sharkey KA, Storr M. A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. Neuropharmacology. 71: 255-63. PMID 23603203 DOI: 10.1016/j.neuropharm.2013.03.029  1
2013 Klein S, Seidler B, Kettenberger A, Sibaev A, Rohn M, Feil R, Allescher HD, Vanderwinden JM, Hofmann F, Schemann M, Rad R, Storr MA, Schmid RM, Schneider G, Saur D. Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity. Nature Communications. 4: 1630. PMID 23535651 DOI: 10.1038/ncomms2626  1
2013 Li YY, Yuece B, Cao HM, Lin HX, Lv S, Chen JC, Ochs S, Sibaev A, Deindl E, Schaefer C, Storr M. Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis. Laboratory Investigation; a Journal of Technical Methods and Pathology. 93: 322-33. PMID 23381627 DOI: 10.1038/labinvest.2012.177  1
2013 Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders. Wiener Medizinische Wochenschrift (1946). 163: 65-72. PMID 23263639 DOI: 10.1007/s10354-012-0169-x  1
2013 Michler T, Storr M, Kramer J, Ochs S, Malo A, Reu S, Göke B, Schäfer C. Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms. American Journal of Physiology. Gastrointestinal and Liver Physiology. 304: G181-92. PMID 23139224 DOI: 10.1152/ajpgi.00133.2012  1
2013 Li K, Feng JY, Li YY, Yuece B, Lin XH, Yu LY, Li YN, Feng YJ, Storr M. Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice. Pancreas. 42: 123-9. PMID 22850623 DOI: 10.1097/MPA.0b013e318259f6f0  1
2013 Gyulai Z, Udvardy A, Cs Bényei A, Fichna J, Gach K, Storr M, Tóth G, Antus S, Berényi S, Janecka A, Sipos A. Synthesis and opioid activity of novel 6-ketolevorphanol derivatives. Medicinal Chemistry (ShāRiqah (United Arab Emirates)). 9: 1-10. PMID 22741803  1
2013 Storr M. Eosinophilic esophagitis: Improvement through aerosolized swallowed fluticasone and esomeprazole | Eosinophile ösophagitis: Verbesserung durch geschlucktes vernebeltes Fluticason und Esomeprazol Medizinische Monatsschrift Fur Pharmazeuten. 36: 270-272.  1
2013 Storr M. Eosinophilic esophagitis: Improvement by swallowed nebulized fluticasone and esomeprazole | Eosinophile ösophagitis: Verbesserung durch geschlucktes vernebeltes fluticason und esomeprazol Arzneimitteltherapie. 31: 174-175.  1
2012 Fichna J, Lapointe T, Chapman K, Janecka A, Vergnolle N, Altier C, Storr MA. New neostigmine-based behavioral mouse model of abdominal pain. Pharmacological Reports : Pr. 64: 1146-54. PMID 23238471  1
2012 Pehl C, Keller J, Allescher HD, Feussner H, Frieling T, Goebel-Stengel M, Gschossmann J, Kuhlbusch-Zicklam R, Mönnikes H, Nguyen HN, Müller M, Schirra J, Storr M, van der Voort I, Yüce B. [Diagnosis of oesophageal reflux by PH, impedance, and bilirubin measurement: recommendations of the German Society of Neurogastroenterology and of the working group for neurogastroenterology of the German Society for Digestive and Metabolic Diseases]. Zeitschrift FüR Gastroenterologie. 50: 1310-32. PMID 23225560 DOI: 10.1055/s-0032-1325483  1
2012 Kaplan GG, Szyszkowicz M, Fichna J, Rowe BH, Porada E, Vincent R, Madsen K, Ghosh S, Storr M. Non-specific abdominal pain and air pollution: a novel association. Plos One. 7: e47669. PMID 23118887 DOI: 10.1371/journal.pone.0047669  1
2012 Schicho R, Storr M. A potential role for GPR55 in gastrointestinal functions. Current Opinion in Pharmacology. 12: 653-8. PMID 23063456 DOI: 10.1016/j.coph.2012.09.009  1
2012 Syed AA, Andrews CN, Shaffer E, Urbanski SJ, Beck P, Storr M. The rising incidence of eosinophilic oesophagitis is associated with increasing biopsy rates: a population-based study. Alimentary Pharmacology & Therapeutics. 36: 950-8. PMID 22994460 DOI: 10.1111/apt.12053  1
2012 Bashashati M, Rezaei N, Bashashati H, Shafieyoun A, Daryani NE, Sharkey KA, Storr M. Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 24: 1102-e566. PMID 22897390 DOI: 10.1111/j.1365-2982.2012.01990.x  1
2012 Andrews CN, Beck PL, Wilsack L, Urbanski SJ, Storr M. Evaluation of endoscopist and pathologist factors affecting the incidence of microscopic colitis. Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 26: 515-20. PMID 22891175  1
2012 Fichna J, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, MaÅ‚ecka-Panas E, Janecka A, Krajewska WM, Storr MA. Transient receptor potential vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment? Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 24: e557-60. PMID 22882778 DOI: 10.1111/j.1365-2982.2012.01999.x  1
2012 Fichna J, Storr MA. Brain-Gut Interactions in IBS. Frontiers in Pharmacology. 3: 127. PMID 22783191 DOI: 10.3389/fphar.2012.00127  1
2012 Andrews CN, Sadowski DC, Lazarescu A, Williams C, Neshev E, Storr M, Au F, Heitman SJ. Unsedated peroral wireless pH capsule placement vs. standard pH testing: a randomized study and cost analysis. Bmc Gastroenterology. 12: 58. PMID 22650250 DOI: 10.1186/1471-230X-12-58  1
2012 Schicho R, Shaykhutdinov R, Ngo J, Nazyrova A, Schneider C, Panaccione R, Kaplan GG, Vogel HJ, Storr M. Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. Journal of Proteome Research. 11: 3344-57. PMID 22574726 DOI: 10.1021/pr300139q  1
2012 Schicho R, Storr M. Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology. 89: 149-55. PMID 22414698 DOI: 10.1159/000336871  1
2012 Bassaganya-Riera J, Viladomiu M, Pedragosa M, De Simone C, Carbo A, Shaykhutdinov R, Jobin C, Arthur JC, Corl BA, Vogel H, Storr M, Hontecillas R. Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis. Plos One. 7: e31238. PMID 22363592 DOI: 10.1371/journal.pone.0031238  1
2012 Hons IM, Storr MA, Mackie K, Lutz B, Pittman QJ, Mawe GM, Sharkey KA. Plasticity of mouse enteric synapses mediated through endocannabinoid and purinergic signaling. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 24: e113-24. PMID 22235973 DOI: 10.1111/j.1365-2982.2011.01860.x  1
2012 Storr M, Allescher HD. Irritable bowel syndrome: a dysfunction of the endocannabinoid system? Gastroenterology. 142: 406-8. PMID 22192431 DOI: 10.1053/j.gastro.2011.12.028  1
2012 Bashashati M, Rezaei N, Andrews CN, Chen CQ, Daryani NE, Sharkey KA, Storr MA. Cytokines and irritable bowel syndrome: where do we stand? Cytokine. 57: 201-9. PMID 22178716 DOI: 10.1016/j.cyto.2011.11.019  1
2012 Fichna J, Dicay M, Lewellyn K, Janecka A, Zjawiony JK, MacNaughton WK, Storr MA. Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. Inflammatory Bowel Diseases. 18: 1137-45. PMID 21953882 DOI: 10.1002/ibd.21873  1
2012 Bashashati M, Storr MA, Nikas SP, Wood JT, Godlewski G, Liu J, Ho W, Keenan CM, Zhang H, Alapafuja SO, Cravatt BF, Lutz B, Mackie K, Kunos G, Patel KD, et al. Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. British Journal of Pharmacology. 165: 1556-71. PMID 21883147 DOI: 10.1111/j.1476-5381.2011.01644.x  1
2012 Storr M. Functional dyspepsia: Acotiamide relieves postprandial dyspeptic symptoms | Funktionelle dyspepsie: Acotiamid lindert postprandiale dyspeptische beschwerden Medizinische Monatsschrift Fur Pharmazeuten. 35.  1
2012 Storr M. Gastroesophageal reflux disease: The reflux inhibitors baclofen and lesogaberan fail in the clinical trial | Gastroösophageale refluxkrankheit: Die refluxinhibitoren baclofen und lesogaberan enttäuschen in der klinischen prüfung Medizinische Monatsschrift Fur Pharmazeuten. 35.  1
2012 Storr M. Chronic constipation: The guanylate cyclase activator linaclotide relieves the symptoms | Chronische obstipation: Der guanylatcyclase-aktivator linaclotid lindert die symptome Medizinische Monatsschrift Fur Pharmazeuten. 35.  1
2012 Storr M. Chronic inflammatory bowel disease: Certolizumab pegol induces remission of Crohn's disease in patients with elevated CRP | Chronisch entzündliche darmerkrankungen: Certolizumab pegol induziert bei morbus-Crohn-patienten mit erhöhtem CRP eine remission Medizinische Monatsschrift Fur Pharmazeuten. 35.  1
2012 Storr M. Irritable bowel syndrome without constipation: Two-week treatment with rifaximin relieves the symptoms over several weeks | Reizdarmsyndrom ohne obstipation: Zweiwöchige therapie mit rifaximin lindert die symptome über mehrere wochen Medizinische Monatsschrift Fur Pharmazeuten. 35.  1
2011 Storr M. [Therapy of gastroesophageal reflux disease (GERD)]. Medizinische Monatsschrift FüR Pharmazeuten. 34: 446-54; quiz 455-6. PMID 22233024  1
2011 Andrews CN, Storr M. The pathophysiology of chronic constipation. Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 25: 16B-21B. PMID 22114753  1
2011 Storr M, Storr M. Chronic constipation: current management and challenges. Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 25: 5B-6B. PMID 22114750  1
2011 Chen CQ, Fichna J, Bashashati M, Li YY, Storr M. Distribution, function and physiological role of melatonin in the lower gut. World Journal of Gastroenterology : Wjg. 17: 3888-98. PMID 22025877 DOI: 10.3748/wjg.v17.i34.3888  1
2011 Alfadda AA, Storr MA, Shaffer EA. Eosinophilic colitis: an update on pathophysiology and treatment. British Medical Bulletin. 100: 59-72. PMID 22012125 DOI: 10.1093/bmb/ldr045  1
2011 Alfadda AA, Storr MA, Shaffer EA. Eosinophilic colitis: epidemiology, clinical features, and current management. Therapeutic Advances in Gastroenterology. 4: 301-9. PMID 21922029 DOI: 10.1177/1756283X10392443  1
2011 Schicho R, Storr M. Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 25: 377-83. PMID 21876860  1
2011 Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu HM, Zimmer A, Lutz B, Mackie K, Bradshaw HB, McCafferty DM, Sharkey KA, Storr M. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflammatory Bowel Diseases. 17: 1651-64. PMID 21744421 DOI: 10.1002/ibd.21538  1
2011 Lin XH, Yuece B, Li YY, Feng YJ, Feng JY, Yu LY, Li K, Li YN, Storr M. A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 23: 862-e342. PMID 21726355 DOI: 10.1111/j.1365-2982.2011.01742.x  1
2011 Stewart MJ, Seow CH, Storr MA. Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 9: 881-90. PMID 21699817 DOI: 10.1016/j.cgh.2011.06.005  1
2011 Congly SE, Gao ZH, Storr M. Duodenal vascular ectasia (DUVE) associated with hematopoietic stem cell transplant. Endoscopy. 43: E197-8. PMID 21590601 DOI: 10.1055/s-0030-1256349  1
2011 Stewart M, Andrews CN, Urbanski S, Beck PL, Storr M. The association of coeliac disease and microscopic colitis: a large population-based study. Alimentary Pharmacology & Therapeutics. 33: 1340-9. PMID 21517923 DOI: 10.1111/j.1365-2036.2011.04666.x  1
2011 Fichna J, Dicay M, Hirota SA, Traboulsi D, Macdonald JA, Janecka A, Beck PL, Zjawiony JK, Macnaughton WK, Storr MA. Differential effects of salvinorin A on endotoxin-induced hypermotility and neurogenic ion transport in mouse ileum. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 23: 583-e212. PMID 21414104 DOI: 10.1111/j.1365-2982.2011.01699.x  1
2011 Kurjak M, Fichna J, Harbarth J, Sennefelder A, Allescher HD, Schusdziarra V, Storr M, Otto B. Effect of GABA-ergic mechanisms on synaptosomal NO synthesis and the nitrergic component of NANC relaxation in rat ileum. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 23: e181-90. PMID 21414101 DOI: 10.1111/j.1365-2982.2011.01688.x  1
2011 Andrews CN, Mintchev P, Neshev E, Fraser HF, Storr M, Bathe OF, Urbanski SJ. Percutaneous endoscopically assisted transenteric full-thickness gastric biopsy: initial experience in humans. Gastrointestinal Endoscopy. 73: 949-54. PMID 21392758 DOI: 10.1016/j.gie.2010.12.037  1
2011 Storr MA. What is nonacid reflux disease? Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 25: 35-8. PMID 21258666  1
2010 Schicho R, Storr M. Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies. Expert Review of Clinical Pharmacology. 3: 193-207. PMID 22111567 DOI: 10.1586/ecp.09.62  1
2010 Schicho R, Nazyrova A, Shaykhutdinov R, Duggan G, Vogel HJ, Storr M. Quantitative metabolomic profiling of serum and urine in DSS-induced ulcerative colitis of mice by (1)H NMR spectroscopy. Journal of Proteome Research. 9: 6265-73. PMID 20886908 DOI: 10.1021/pr100547y  1
2010 Papay KD, Falck VG, Poulsen SS, Panaccione R, Rehfeld JF, Storr MA. Juvenile polyposis of the stomach--a novel cause of hypergastrinemia. Nature Reviews. Gastroenterology & Hepatology. 7: 583-8. PMID 20808292 DOI: 10.1038/nrgastro.2010.138  1
2010 Bashashati M, Andrews C, Ghosh S, Storr M. Botulinum toxin in the treatment of diffuse esophageal spasm. Diseases of the Esophagus : Official Journal of the International Society For Diseases of the Esophagus / I.S.D.E. 23: 554-60. PMID 20459446 DOI: 10.1111/j.1442-2050.2010.01065.x  1
2010 Fichna J, Perlikowska R, Gach K, do-Rego JC, Cravezic A, Janecka A, Storr MA. The novel endomorphin degradation blockers Tyr-Pro-DClPhe-Phe-NH (EMDB-1) and Tyr-Pro-Ala-NH (EMDB-2) prolong endomorphin-2 action in rat ileum in vitro. Chemical Biology & Drug Design. 76: 77-81. PMID 20456368 DOI: 10.1111/j.1747-0285.2010.00977.x  1
2010 Gach K, do-Rego JC, Fichna J, Storr M, Delbro D, Toth G, Janecka A. Synthesis and biological evaluation of novel peripherally active morphiceptin analogs. Peptides. 31: 1617-24. PMID 20434497 DOI: 10.1016/j.peptides.2010.04.018  1
2010 Czakó B, Marton J, Berényi S, Gach K, Fichna J, Storr M, Tóth G, Sipos A, Janecka A. Synthesis and opioid activity of novel 6-substituted-6-demethoxy-ethenomorphinans. Bioorganic & Medicinal Chemistry. 18: 3535-42. PMID 20413312 DOI: 10.1016/j.bmc.2010.03.068  1
2010 Lee R, Storr M, Hershfield NB. A case of Conn's syndrome revealed after oral sodium phosphate (Fleet) preparation for colonoscopy. Journal of Digestive Diseases. 11: 111-4. PMID 20402838 DOI: 10.1111/j.1751-2980.2010.00425.x  1
2010 Fraser H, Neshev E, Storr M, Urbanski SJ, Andrews CN. A novel method of full-thickness gastric biopsy via a percutaneous, endoscopically assisted, transenteric approach. Gastrointestinal Endoscopy. 71: 831-4. PMID 20363426 DOI: 10.1016/j.gie.2009.11.048  1
2010 Storr M, Emmerdinger D, Diegelmann J, Pfennig S, Ochsenkühn T, Göke B, Lohse P, Brand S. The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's disease. Plos One. 5: e9453. PMID 20195480 DOI: 10.1371/journal.pone.0009453  1
2010 Storr MA, Bashashati M, Hirota C, Vemuri VK, Keenan CM, Duncan M, Lutz B, Mackie K, Makriyannis A, Macnaughton WK, Sharkey KA. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 22: 787-96, e223. PMID 20180825 DOI: 10.1111/j.1365-2982.2010.01478.x  1
2010 Yüce B, Kemmer M, Qian G, Müller M, Sibaev A, Li Y, Kreis ME, Storr M. Cannabinoid 1 receptors modulate intestinal sensory and motor function in rat. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 22: 672-e205. PMID 20158615 DOI: 10.1111/j.1365-2982.2010.01473.x  1
2010 Fichna J, Gach K, Perlikowska R, Cravezic A, Bonnet JJ, do-Rego JC, Janecka A, Storr MA. Novel endomorphin analogues with antagonist activity at the mu-opioid receptor in the gastrointestinal tract. Regulatory Peptides. 162: 109-14. PMID 20083143 DOI: 10.1016/j.regpep.2010.01.001  1
2010 Williams JJ, Beck PL, Andrews CN, Hogan DB, Storr MA. Microscopic colitis -- a common cause of diarrhoea in older adults. Age and Ageing. 39: 162-8. PMID 20065357 DOI: 10.1093/ageing/afp243  1
2010 Perlikowska R, Fichna J, Wyrebska A, Poels J, Vanden Broeck J, Toth G, Storr M, do Rego JC, Janecka A. Design, synthesis and pharmacological characterization of endomorphin analogues with non-cyclic amino acid residues in position 2. Basic & Clinical Pharmacology & Toxicology. 106: 106-13. PMID 19874287 DOI: 10.1111/j.1742-7843.2009.00476.x  1
2010 Li YY, Li YN, Ni JB, Chen CJ, Lv S, Chai SY, Wu RH, Yüce B, Storr M. Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 22: 350-e88. PMID 19840270 DOI: 10.1111/j.1365-2982.2009.01419.x  1
2009 Fichna J, Schicho R, Janecka A, Zjawiony JK, Storr M. Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. Drug News & Perspectives. 22: 383-92. PMID 19890495 DOI: 10.1358/dnp.2009.22.7.1400219  1
2009 Fichna J, Schicho R, Andrews CN, Bashashati M, Klompus M, McKay DM, Sharkey KA, Zjawiony JK, Janecka A, Storr MA. Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 21: 1326-e128. PMID 19650775 DOI: 10.1111/j.1365-2982.2009.01369.x  1
2009 Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflammatory Bowel Diseases. 15: 1678-85. PMID 19408320 DOI: 10.1002/ibd.20960  1
2008 Storr MA, Yüce B, Andrews CN, Sharkey KA. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 20: 857-68. PMID 18710476 DOI: 10.1111/j.1365-2982.2008.01175.x  1
2008 Storr M, Andrews CN. Medical management of irritable bowel syndrome in 2008: current and future directions. Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 22: 673-5. PMID 18701942  0.6
2008 Andrews CN, Storr M. Evaluation of lower functional gut disorders. Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 22: 614-6. PMID 18629389  0.6
2008 Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yüce B, Sibaev A, Massa F, Buckley NE, Lutz B, Göke B, Brand S, Patel KD, Sharkey KA. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. Journal of Molecular Medicine (Berlin, Germany). 86: 925-36. PMID 18493729 DOI: 10.1007/s00109-008-0359-6  1
2007 Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Current Opinion in Pharmacology. 7: 575-82. PMID 17904903 DOI: 10.1016/j.coph.2007.08.008  1
2007 Yuece B, Sibaev A, Broedl UC, Marsicano G, Göke B, Lutz B, Allescher HD, Storr M. Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 19: 744-53. PMID 17727394 DOI: 10.1111/j.1365-2982.2007.00975.x  0.68
2007 Yüce B, Sibaev A, Haaken A, Saur D, Allescher HD, Göke B, Timmermans JP, Storr M. ORL-1 receptor mediates the action of nociceptin on ascending myenteric reflex pathways in rats. Gastroenterology. 133: 574-86. PMID 17681177 DOI: 10.1053/j.gastro.2007.05.016  0.32
2006 Sibaev A, Massa F, Yüce B, Marsicano G, Lehr HA, Lutz B, Göke B, Allescher HD, Storr M. CB1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice. Journal of Molecular Medicine (Berlin, Germany). 84: 513-20. PMID 16501934 DOI: 10.1007/s00109-006-0040-x  0.68
2006 Massa F, Sibaev A, Marsicano G, Blaudzun H, Storr M, Lutz B. Vanilloid receptor (TRPV1)-deficient mice show increased susceptibility to dinitrobenzene sulfonic acid induced colitis. Journal of Molecular Medicine (Berlin, Germany). 84: 142-6. PMID 16389550 DOI: 10.1007/s00109-005-0016-2  0.68
2005 Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. Journal of Molecular Medicine (Berlin, Germany). 83: 944-54. PMID 16133420 DOI: 10.1007/s00109-005-0698-5  0.68
2004 Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, Lutz B. The endogenous cannabinoid system protects against colonic inflammation. The Journal of Clinical Investigation. 113: 1202-9. PMID 15085199 DOI: 10.1172/JCI19465  0.68
2004 Storr M, Sibaev A, Marsicano G, Lutz B, Schusdziarra V, Timmermans JP, Allescher HD. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. American Journal of Physiology. Gastrointestinal and Liver Physiology. 286: G110-7. PMID 12893627 DOI: 10.1152/ajpgi.00148.2003  0.68
2002 Storr M, Koppitz P, Sibaev A, Saur D, Kurjak M, Franck H, Schusdziarra V, Allescher HD. Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro. Journal of Pineal Research. 33: 101-8. PMID 12153444 DOI: 10.1034/j.1600-079X.2002.02909.x  0.56
1998 Storr M, Weigert N, Fellbaum C, Classen M. [Polyposis of the gastrointestinal tract as a manifestation of diffuse follicular lymphatic hyperplasia]. Deutsche Medizinische Wochenschrift (1946). 123: 347-52. PMID 9551038 DOI: 10.1055/s-2007-1023970  1
Show low-probability matches.